about
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.Co-operative additive effects between HLA alleles in control of HIV-1Progression to AIDS in South Africa is associated with both reverting and compensatory viral mutations.Task shifting of antiretroviral treatment from doctors to primary-care nurses in South Africa (STRETCH): a pragmatic, parallel, cluster-randomised trial.HIV control through a single nucleotide on the HLA-B locus.Streamlining tasks and roles to expand treatment and care for HIV: randomised controlled trial protocolHLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703Southern African Treatment Resistance Network (SATuRN) RegaDB HIV drug resistance and clinical management database: supporting patient management, surveillance and research in southern Africa.Prevalence of HIV type-1 drug-associated mutations in pre-therapy patients in the Free State, South Africa.Adalimumab treatment of life-threatening tuberculosis.Adult antiretroviral therapy guidelines 2017.Effectiveness of Antiretroviral Treatment in a South African Program A Cohort StudyHaemodialysis catheter-related bloodstream infections at Universitas Academic Hospital, Bloemfontein: should we change our empiric antibiotics?Antimicrobial resistance patterns in outpatient urinary tract infections - the constant need to revise prescribing habitsChapter 12. Managing the HIV Epidemic in the Developing World – Progress and ChallengesSouthern African HIV Clinicians Society Guidance on the use of dolutegravir in first-line antiretroviral therapyAppropriate clinical use of darunavir 800 mg
P50
Q33647567-23E350E0-70B0-42B7-948D-D4F462AE5630Q34456570-0AEF8683-6849-4B8E-9075-5F7E348C6F14Q34841789-177D01D9-9384-4A56-8F5D-73757BF8F1EAQ36233895-FBB6DF69-DBBD-43C1-93AF-8D68097D6269Q36363448-39A18EC5-A74A-4D8E-A16F-77608073343EQ36649226-29A23A8E-AF57-4816-980F-9A3AC6833FD8Q37081581-06753757-D5B7-47E9-97C9-8797053D4CB6Q39209322-6ECA3045-8A09-48CD-848A-E47C5A1E2C76Q46048112-07515FDC-616D-4E11-9087-EA75ADED94B4Q48013777-1D1BF17B-3EAB-41A3-8799-D46A483B46D5Q52641448-FE11A7CC-601F-4C31-A386-22B2D693B7DAQ57343454-28B7DB2B-ABA3-4636-80D2-C4A3A08A71FAQ58427618-9CCEEBC4-0DE9-4BFC-AD48-B1F02B0C8144Q58427621-C796AB58-A6C0-408E-9629-7B0AE214817CQ58427629-E93A5E4B-0346-4D71-BFA3-127939252E92Q93355458-6BFCE20F-1D6C-4B57-A963-8019DA40B2D5Q93355465-34B41658-0A9C-43EC-B12B-608453A8DCD2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Cloete van Vuuren
@ast
Cloete van Vuuren
@en
Cloete van Vuuren
@es
Cloete van Vuuren
@nl
Cloete van Vuuren
@sl
type
label
Cloete van Vuuren
@ast
Cloete van Vuuren
@en
Cloete van Vuuren
@es
Cloete van Vuuren
@nl
Cloete van Vuuren
@sl
prefLabel
Cloete van Vuuren
@ast
Cloete van Vuuren
@en
Cloete van Vuuren
@es
Cloete van Vuuren
@nl
Cloete van Vuuren
@sl
P106
P31
P496
0000-0002-9095-0039